ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pancreatic Cancer
Non-Small-Cell Lung Carcinoma
Colorectal Cancer
Stomach Cancer
Cancer
Esophageal Cancer
Prostatic Cancer

Adenocarcinoma trials near Charlotte, NC, USA:

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

Enrolling
Pancreatic Ductal Adenocarcinoma
Non Small Cell Lung Cancer
Drug: Pemetrexed
Drug: Carboplatin + Pemetrexed

Phase 1, Phase 2

Phanes Therapeutics

Huntersville, North Carolina, United States of America and 5 other locations

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), tar...

Enrolling
Pancreatic Adenocarcinoma
Other Solid Tumors
Biological: Autologous, engineered T Cells targeting TP53 R175H

Phase 1

AstraZeneca
AstraZeneca

Charlotte, North Carolina, United States and 17 other locations

Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Drug: nab-paclitaxel
Drug: gemcitabine

Phase 2

Astellas
Astellas

Charlotte, North Carolina, United States and 135 other locations

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced...

Enrolling
Endometrial Adenocarcinoma
Appendiceal Adenocarcinoma
Drug: APL-5125

Phase 1, Phase 2

Apollo Therapeutics

Huntersville, North Carolina, United States of America and 8 other locations

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy...

Enrolling
Solid Tumors
Drug: Palbociclib
Drug: Olaparib

Phase 1

Incyte
Incyte

Huntersville, North Carolina, United States and 45 other locations

a dose expansion phase to confirm the dose and combination with bevacizumab. Approximately 500 adult participants with NSCLC, gastroesophageal adenocarcinoma...

Active, not recruiting
Gastroesophageal Adenocarcinoma
Advanced Solid Tumors
Drug: ABBV-400
Drug: Trifluridine/Tipiracil

Phase 1

AbbVie
AbbVie

Huntersville, North Carolina, United States of America and 86 other locations

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant sol...

Enrolling
Pancreatic Ductal Adenocarcinoma (PDAC)
Non-small Cell Lung Cancer (NSCLC)
Drug: RMC-6236
Drug: RMC-9805

Phase 1

Revolution Medicines
Revolution Medicines

Huntersville, North Carolina, United States of America and 16 other locations

This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer ha...

Enrolling
Advanced Solid Cancer
KRAS G12D Mutation
Drug: ARV-806

Phase 1, Phase 2

Arvinas
Arvinas

Huntersville, North Carolina, United States and 3 other locations

This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminar...

Active, not recruiting
Pancreatic Adenocarcinoma
Non-small Cell Lung Cancer (NSCLC)
Drug: IMM-1-104 + pembrolizumab (Treatment Group E)
Drug: IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)

Phase 1, Phase 2

Immuneering Corporation

Charlotte, North Carolina, United States and 19 other locations

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in sub...

Enrolling
Esophageal Adenocarcinoma
Metastatic Cancer
Drug: TJ033721 (givastomig)
Drug: TJ033721 (givastomig) , nivolumab, chemotherapy

Phase 1

I-Mab Biopharma

Huntersville, North Carolina, United States of America and 20 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems